U.S. life expectancy hit an all-time high in 2024, CDC says

U.S. life expectancy rose to a record 79.0 years in 2024, driven by declines in death rates from COVID-19, heart disease (heart disease mortality down ~3% for the second year), cancer and a >14% drop in unintentional-injury deaths (including overdoses). Total deaths in 2024 were about 3.07 million, roughly 18,000 fewer than 2023, and preliminary 2025 counts suggest about 3.05 million; COVID-19 dropped out of the top 10 causes of death. For investors, the data signal modestly improving population health trends that could influence long-term liabilities for life insurers, pension plans and healthcare demand, but the near-term market impact is limited.

Analysis

Market structure: Improving U.S. life expectancy (to 79 in 2024) is a net positive for managed-care, medtech and senior-living demand while creating bifurcated outcomes across insurers — annuity writers face longer payout duration, term-life writers see lower claim frequency. Expect relative winners: UNH, CVS (Medicare Advantage scale) and WELL/VTR (senior housing REITs); relative losers: annuity-heavy carriers (PRU, MET) and some short-duration hospital operators if elective acute volumes normalize. Demand-side: longer lifespans shift capital toward long-duration assets (insurer/pension hedging), healthcare services and durable medical devices over discretionary healthcare spend; supply-side capacity for senior housing and medtech will reprice over 1–3 years.

Risk assessment: Tail risks include renewed pandemic waves, opioid resurgence, or aggressive Medicare/drug-pricing regulation; any of these could reverse mortality gains within 6–18 months and reprice healthcare equities >15%. Hidden dependency: actuarial assumption revisions by large pension funds/insurers may trigger forced bond buying or capital raises — expect volatility in long-dated Treasuries and IG corporates when assumptions change. Key catalysts: CMS rule releases, Oct Medicare Advantage enrollment figures, and insurer 10-K actuarial updates over the next 3–9 months.

Trade implications: Construct concentrated, time-bound exposures: overweight large-cap managed care (UNH) and medtech (MDT) for 6–18 months while underweight annuity-focused insurers (PRU, MET). Consider pair trades (long WELL or VTR vs short MET) to capture senior-housing secular demand vs annuity liability pressure. Use options to capsulate views: 9–15 month call spreads on UNH and long-dated puts on PRU/MET to limit downside. Rebalance within 6–12 months around CMS and earnings prints.

Contrarian angles: Consensus treats improved longevity as uniformly positive for “healthcare” — it is not. Markets likely under-price the multi-year liability shock to annuities and pensions; that mispricing could compress annuity writers’ equity by 10–25% if actuarial lifespans are uprated aggressively. Historical parallel: post-2009 longevity assumption shifts led to multi-year insurance sector underperformance; same dynamics could repeat as mortality trends improve. Unintended consequence: stronger longevity could increase long-duration bond demand, pressuring yields and creating a crowded long-duration trade vulnerable to faster-than-expected growth or inflation reversals.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth (UNH) over next 4 weeks, targeting +12–18% upside in 12 months; set a hard stop-loss at -8% to account for policy/regulatory risk around CMS announcements.
• Overweight senior-housing REITs with a 1.5–2% position in Welltower (WELL) or Ventas (VTR), horizon 12–36 months to capture demand as cohort aged 75+ grows; trim if occupancy improvements fail to exceed 200 bps within 12 months.
• Initiate a 1.5% short or underweight position in Prudential (PRU) or MetLife (MET) targeting 10–25% downside over 6–24 months, reflecting higher annuity liabilities; hedge with 9–15 month ATM put options sized to cover 50% of notional exposure.
• Execute a pair trade: long 2% WELL (or VTR) and short 1.5% MET, holding 9–18 months; monitor insurer actuarial disclosure window (Q4 filings) — if actuarial lifespan increases >0.5 years, add to the short.
• Buy a 9–12 month call spread on UNH (ATM to +10% strikes) sized to 0.5–1% of portfolio to express upside with limited premium, and buy 12-month 10% OTM puts on PRU sized to 0.5% as asymmetric downside protection while cost remains <0.2% portfolio.